ARVINAS, INC.
Develops protein degradation drugs for oncology & neuroscience, targeting undruggable proteins.
ARVN | NDAQ
Overview
Corporate Details
- ISIN(s):
- US04335A1051
- LEI:
- Country:
- United States of America
- Address:
- 395 WINCHESTER AVE, 6511 NEW HAVEN
- Website:
- https://www.arvinas.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Arvinas, Inc. is a clinical-stage biopharmaceutical company pioneering the development of a new class of medicines based on targeted protein degradation. The company's proprietary PROTAC® (PROteolysis TArgeting Chimera) platform utilizes the body's natural protein disposal system to selectively target and degrade disease-causing proteins. This innovative approach enables the development of therapeutics against targets previously considered "undruggable." Arvinas maintains an expansive development pipeline focused on creating transformative treatments for patients with serious illnesses, primarily in the areas of oncology and neuroscience.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ARVINAS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ARVINAS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ARVINAS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
